All In Biotech

Drug Trial Radar · NCT03819881

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

A Phase 1b, Multi-centered, Randomized, Double-blind, Placebo-controlled, Parallel Group, Three Sequential Part Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

Last checked: Nov 19, 2026Latest source record: Jan 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 10, 2018

Primary completion

Nov 2019

Study completion Nov 2019

Sponsor

Lead sponsor
Siolta Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Integrium
First posted
Jan 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability of STMC-103H compared to placebo in allergic subjects who are otherwise healthy.

Conditions

  • Atopic Immunoglobulin E-Mediated Allergic Disorder

Interventions

  • STMC-103HBiological

    Live bacterial product

  • PlaceboBiological

    Inactive placebo substance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with treatment-related adverse events (AEs) assessed as mild, moderate and severe, from baseline to day 29.Time frame: From baseline to day 57
  2. Incidence of abnormal laboratory test results from baseline to day 29Time frame: From baseline to day 29
  3. Change in blood pressure from baseline to day 57Time frame: From baseline to day 57
  4. Change in respiration rate from baseline to day 57Time frame: From baseline to day 57
  5. Change in heart rate from baseline to day 57Time frame: From baseline to day 57

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Bensch Clinical Research LLC

    Stockton, California · Recruiting

  • Orange County Research Center

    Tustin, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.